Department of Genomic Medicine, International Center of Neuroscience & Genomic Medicine, EuroEspes Biomedical Research Center, Bergondo, Corunna, 15165, Spain.
Department of Genomics & Pharmacogenomics, International Center of Neuroscience & Genomic Medicine, EuroEspes Biomedical Research Center, Bergondo, Corunna, 15165, Spain.
Pharmacogenomics. 2023 Jan;24(1):27-57. doi: 10.2217/pgs-2022-0137. Epub 2023 Jan 11.
Anxiety and depression coexist with cognitive impairment in Alzheimer's disease along with other concomitant disorders (>60%), which require multipurpose treatments. Polypharmaceutical regimens cause drug-drug interactions and adverse drug reactions, potentially avoidable in number and severity with the implementation of pharmacogenetic procedures. The accumulation of defective variants (>30 genes per patient in more than 50% of cases) in pharmagenes (pathogenic, mechanistic, metabolic, transporter, pleiotropic) influences the therapeutic response to antidementia, antidepressant and anxiolytic drugs in polyvalent regimens. , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , and variants affect anxiety and depression in Alzheimer's disease.
阿尔茨海默病患者常同时伴有焦虑和抑郁，以及其他共病（>60%），需要多方面的治疗。多药物治疗方案会导致药物相互作用和药物不良反应，通过实施药物遗传学程序，可以在数量和严重程度上避免这些问题。在药物基因组学（致病、机制、代谢、转运蛋白、多效性）中，缺陷变异体（>30 个基因/患者，在 50%以上的病例中）的积累会影响多药物治疗方案中抗痴呆、抗抑郁和抗焦虑药物的治疗反应。载脂蛋白 E ε4 等位基因、TREM2 变体和其他基因影响阿尔茨海默病患者的焦虑和抑郁。
